Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00627861 · ClinicalTrials.gov registry record · NA
Combined Renin Inhibition/Beta-blockade
A NA study, sponsored by The Rogosin Institute.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00627861 is a NA study that was terminated before completion, run by The Rogosin Institute. The registered enrollment target is 1 participants.
The verdict
NCT00627861, a NA study, was terminated before completion, sponsored by The Rogosin Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been developed. However, the kidney responds to these drug treatments by producing greater amounts of renin. This high level of renin can reduce the effectiveness of some of these medications, ultimately causing the blood pressure to rise. This is one reason why blood pressure can be difficult to control in a certain percentage of patients. The hypothesis to be tested in the proposed study is that beta-adrenergic blockade (β-blockade), when superimposed upon aliskiren, a drug that competitively inhibits plasma renin activity (PRA) but stimulates the release of renin by the kidneys (plasma renin concentration \[PRC\]), can suppress the reactive increase in PRC that occurs during aliskiren monotherapy. The primary aim of this study is to measure plasma renin concentration (PRC) and plasma renin activity (PRA) levels during renin inhibition with aliskiren and combined renin inhibition/β-blocker treatment to determine whether the addition of a β-blocker attenuates the rise in plasma renin concentration (PRC). A secondary aim is to determine whether combined treatment further suppresses PRA and blood pressure.
Interventions
- DRUG Aliskiren
- DRUG Extended-release metoprolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00627861
The ClinicalTrials.gov registry entry for NCT00627861 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00627861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00627861 about?
NCT00627861 is a clinical study titled "Combined Renin Inhibition/Beta-blockade". Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been ...
What is the current status of trial NCT00627861?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00627861?
The interventions under investigation include: Aliskiren (DRUG), Extended-release metoprolol (DRUG).
Who is sponsoring clinical trial NCT00627861?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.